108 related articles for article (PubMed ID: 28377078)
1. Pathogen safety and characterisation of a highly purified human alpha
Kee S; Weber D; Popp B; Nowak T; Schäfer W; Gröner A; Roth NJ
Biologicals; 2017 May; 47():25-32. PubMed ID: 28377078
[TBL] [Abstract][Full Text] [Related]
2. Biochemical comparison of four commercially available human α
Boerema DJ; An B; Gandhi RP; Papineau R; Regnier E; Wilder A; Molitor A; Tang AP; Kee SM
Biologicals; 2017 Nov; 50():63-72. PubMed ID: 28882403
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
4. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.
Kolarich D; Turecek PL; Weber A; Mitterer A; Graninger M; Matthiessen P; Nicolaes GA; Altmann F; Schwarz HP
Transfusion; 2006 Nov; 46(11):1959-77. PubMed ID: 17076852
[TBL] [Abstract][Full Text] [Related]
6. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products.
Cowden DI; Fisher GE; Weeks RL
Curr Med Res Opin; 2005 Jun; 21(6):877-83. PubMed ID: 15969888
[TBL] [Abstract][Full Text] [Related]
7. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
8. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
9. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.
Stocks JM; Brantly M; Pollock D; Barker A; Kueppers F; Strange C; Donohue JF; Sandhaus R
COPD; 2006 Mar; 3(1):17-23. PubMed ID: 17175661
[TBL] [Abstract][Full Text] [Related]
10. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).
Sandhaus RA; Stocks J; Rouhani FN; Brantly M; Strauss P
COPD; 2014 Feb; 11(1):17-25. PubMed ID: 23822603
[TBL] [Abstract][Full Text] [Related]
11. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
12. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the liquid and lyophilized formulations of Prolastin®-C for Alpha
Arora V; Cruz M; Lang J; Klos AM; Merritt WK; Price J; Taylor G; Vandeberg P; Wee K; Willis T
Biologicals; 2019 Nov; 62():77-84. PubMed ID: 31522909
[TBL] [Abstract][Full Text] [Related]
14. Characterisation and virus safety of alpha 1-proteinase inhibitor.
Coan MH; Dobkin MB; Brockway WJ; Mitra G
Eur Respir J Suppl; 1990 Mar; 9():35s-38s. PubMed ID: 2340049
[TBL] [Abstract][Full Text] [Related]
15. Large-scale purification of high purity α1-antitrypsin from Cohn Fraction IV with virus inactivation by solvent/detergent and dry-heat treatment.
Huangfu C; Zhang J; Ma Y; Jia J; Li J; Lv M; Ma X; Zhao X; Zhang J
Biotechnol Appl Biochem; 2018 May; 65(3):446-454. PubMed ID: 29072333
[TBL] [Abstract][Full Text] [Related]
16. Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity.
Mattes E; Matthiessen HP; Turecek PL; Schwarz HP
Vox Sang; 2001 Jul; 81(1):29-36. PubMed ID: 11520413
[TBL] [Abstract][Full Text] [Related]
17. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
18. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
19. Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process.
Barnette D; Roth NJ; Hotta J; Cai K; Gall M; Hartwell R; Kent JD; Willis T
Biologicals; 2012 Jul; 40(4):247-53. PubMed ID: 22579294
[TBL] [Abstract][Full Text] [Related]
20. Ethanol dependence of alpha 1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases.
Matthiessen HP; Willemse J; Weber A; Turecek PL; Deiteren K; Hendriks D; Ehrlich HJ; Schwarz HP
Transfusion; 2008 Feb; 48(2):314-20. PubMed ID: 18028276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]